CNH Industrial N.V. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CNH Industrial N.V. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.10B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.84B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $24.69B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $23.55B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $19.50B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $14.78B | Nov 30, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.35B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $17.06B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $22.08B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $21.54B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $17.80B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $13.08B | Nov 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $510.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.28B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.03B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.72B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($493.00M) | Nov 30, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $924.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.04B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $866.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $642.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $493.00M | Nov 30, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.88B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.71B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.86B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.75B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $1.45B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.30B | Nov 30, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.97B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $907.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $557.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $4.08B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.53B | Nov 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.75B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $42.93B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $46.27B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $39.38B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $49.42B | Nov 30, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.92B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $35.17B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $38.12B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $32.41B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $42.56B | Nov 30, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.58B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.61B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.32B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.21B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.84B | Nov 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.51B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.31B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $9.65B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $7.91B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.82B | Nov 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.58B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.19B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.32B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.38B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $5.04B | Feb 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Nov 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Nov 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.24B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1.25B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 1.29B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 1.34B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 1.36B | Nov 30, 2023 |